The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 11, 2019

Filed:

Mar. 03, 2014
Applicants:

Hyesook Kim, Bloomfield Hills, MI (US);

Sohee Kim, Seoul, KR;

Inventors:

Hyesook Kim, Bloomfield Hills, MI (US);

Sohee Kim, Seoul, KR;

Assignee:

Detroit R&D, Inc., Detroit, MI (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
G01N 33/53 (2006.01); G01N 33/574 (2006.01); A61K 31/496 (2006.01); A61K 31/7076 (2006.01); G01N 33/50 (2006.01); A61K 31/433 (2006.01);
U.S. Cl.
CPC ...
G01N 33/57496 (2013.01); A61K 31/496 (2013.01); A61K 31/7076 (2013.01); G01N 33/5011 (2013.01); G01N 33/5091 (2013.01); G01N 33/57415 (2013.01); G01N 33/57419 (2013.01); G01N 33/57423 (2013.01); G01N 33/57438 (2013.01); A61K 31/433 (2013.01); G01N 2400/02 (2013.01);
Abstract

A method of characterizing the protein O-GlcNAcylation site-specificity of an antibody. A method of detecting or quantitating the expression of site-specific O-GlcNAcylated proteins expressed in cells and biological samples. A method of diagnosing cancer in a host based on the cellular expression of site-specific O-GlcNAcylated proteins. A method of screening anti-cancer compounds according to their ability to increase a level O-GlcNAcylation of oncogene or tumor suppressor proteins. Methods of treating cancer in an animal host by administering compounds that increase a level of O-GlcNAcylated c-myc or p53 in cancer cells. A method of distinguishing subclasses of pancreatic cancer according to the sensitivity of pancreatic cancer cells to an imidazole derivative, and a method of personalized pancreatic cancer treatment delivered according to the sensitivity subclasses.


Find Patent Forward Citations

Loading…